semaglutide versus tirzepatide side effects caused roughly half as many patients to stop treatment because of gastrointestinal as semaglutide. In the first major head-to-head obesity trial, GI side effects caused treatment discontinuation in: Tirzepatide Why You Might Tolerate One

No product testing

Patients should immediately report any unexpected symptoms or changes in health to their healthcare provider to address potential adverse effects proactively

Start low, even coming from a high dose Most switch protocols start tirzepatide at 2.55 mg/week regardless of the semaglutide dose someone was previously on, then re-titrate from there to limit GI side effects

Its pathogenesis is thought to involve various factors, including insulin resistance, lipotoxicity, gut/nutrient-derived signals, adipocytokines, oxidative stress, and genetic factors

Never share the pen between people, and avoid combining with other injectable medicines

FAQs What is Longevity Medicine